Zynex (ZYXI) Expected to Announce Earnings on Tuesday

Zynex (NASDAQ:ZYXI) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $53.65 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Zynex Trading Up 1.1 %

Shares of ZYXI stock opened at $7.35 on Friday. The business’s fifty day moving average price is $7.75 and its 200 day moving average price is $8.03. Zynex has a 1-year low of $7.00 and a 1-year high of $13.19. The firm has a market capitalization of $234.07 million, a PE ratio of 49.00 and a beta of 0.81. The company has a debt-to-equity ratio of 1.66, a current ratio of 3.94 and a quick ratio of 3.15.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Zynex in a report on Friday, December 6th.

Insider Buying and Selling

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the sale, the chief financial officer now owns 19,738 shares of the company’s stock, valued at approximately $151,587.84. This represents a 33.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 30,000 shares of company stock valued at $227,100 over the last quarter. Company insiders own 52.13% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.